Pharmaceuticals (Jan 2022)

Aptamer-Based Lateral Flow Assays: Current Trends in Clinical Diagnostic Rapid Tests

  • Marjan Majdinasab,
  • Mihaela Badea,
  • Jean Louis Marty

DOI
https://doi.org/10.3390/ph15010090
Journal volume & issue
Vol. 15, no. 1
p. 90

Abstract

Read online

The lateral flow assay (LFA) is an extensively used paper-based platform for the rapid and on-site detection of different analytes. The method is user-friendly with no need for sophisticated operation and only includes adding sample. Generally, antibodies are employed as the biorecognition elements in the LFA. However, antibodies possess several disadvantages including poor stability, high batch-to-batch variation, long development time, high price and need for ethical approval and cold chain. Because of these limitations, aptamers screened by an in vitro process can be a good alternative to antibodies as biorecognition molecules in the LFA. In recent years, aptamer-based LFAs have been investigated for the detection of different analytes in point-of-care diagnostics. In this review, we summarize the applications of aptamer technology in LFAs in clinical diagnostic rapid tests for the detection of biomarkers, microbial analytes, hormones and antibiotics. Performance, advantages and drawbacks of the developed assays are also discussed.

Keywords